Related Experiment Video
Updated: Sep 26, 2026

Purification of Ubiquitinated p53 Proteins from Mammalian Cells
Published on: March 21, 2022
Protecting p53 from degradation
1Department of Surgery and Molecular Oncology, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, Scotland, U.K. s.lain@dundee.ac.uk
Abstract:
Inactivation of the p53 function is a common event in cancer. Approx. 50% of human tumours express mutant p53 and there is evidence that in others, including many childhood tumours, p53 function is impaired in other ways. These defects on p53 function may be due to the alteration of cellular factors that modulate p53 or to the expression of viral oncoproteins. Radiotherapy and many of the chemotherapeutic drugs currently used in cancer treatment are potent activators of p53. However, most of these therapies have a serious drawback; that is, the long-term consequences of their DNA-damaging effects. Understanding the mechanisms regulating p53 stability is crucial for the development of new strategies to activate p53 non-genotoxically. Here we describe the effect of a potent activator of the p53 response, the nuclear export inhibitor leptomycin B, on Mdm2 degradation and we provide evidence for the oligomerization of the p14ARF tumour suppressor and Mdm2 inhibitor in response to oxidative stress.
Insights
Cancer cells often inactivate the p53 protein, a key tumor suppressor. This study explores non-damaging ways to activate p53, focusing on leptomycin B
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Inactivation of the p53 tumor suppressor protein is prevalent in approximately 50% of human cancers.
- Impaired p53 function, common in various cancers including childhood tumors, can result from altered cellular factors or viral oncoproteins.
- Current cancer therapies like radiotherapy and chemotherapy activate p53 but cause long-term DNA damage.
Purpose of the Study:
- To investigate novel strategies for non-genotoxic p53 activation.
- To understand mechanisms regulating p53 stability for improved cancer treatment.
- To examine the effects of leptomycin B on Mdm2 degradation and p14ARF oligomerization.
Main Methods:
- Utilized leptomycin B, a nuclear export inhibitor, to study p53 response activation.
- Investigated Mdm2 degradation pathways.
- Assessed the oligomerization of p14ARF in response to oxidative stress.
Main Results:
- Leptomycin B effectively activates the p53 response.
- Observed Mdm2 degradation influenced by leptomycin B.
- Provided evidence for p14ARF oligomerization under oxidative stress conditions.
Conclusions:
- Understanding p53 regulation is key to developing non-genotoxic cancer therapies.
- Leptomycin B shows potential for activating p53 without DNA damage.
- Oxidative stress induces p14ARF oligomerization, impacting Mdm2 inhibition.
Related Concept Videos
Abnormal Proliferation
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle
Negative Regulator Molecules
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...

